Cooper Companies offers resilient medical-device cash flows and a probability-weighted $91.33 five-year value, but near-term destocking, litigation, and MIUDELLA competition temper conviction.
Overview
Cooper Companies is a global medical-device manufacturer built around CooperVision contact lenses and CooperSurgical fertility, genomics, surgical, and contraception products. Its revenue is supported by recurring consumables sold through practitioners, optical retailers, IVF clinics, and hospitals across more than 130 countries. **The long-term case rests on premium daily-lens conversion, pediatric myopia, and IVF growth**, while regulatory barriers and clinical switching costs support a durable number-two global contact-lens position and leadership by active wearers. Q3 FY2026 revenue was $1.066 billion, up 1% reported and organically but $34 million below consensus; adjusted EPS of $1.15 beat estimates, non-GAAP operating margin reached 26%, and free cash flow rose 66% to $273.0 million. Management cut FY26 sales guidance to $4.229 billion-$4.252 billion and adjusted EPS to $4.51-$4.55, reflecting destocking and APAC pressure. **Valuation is discounted at roughly 14.3x-15.0x forward non-GAAP P/E**, versus historical averages, while buybacks and more than $2.2 billion of targeted FY28 cumulative FCF provide support. Near-term catalysts are channel normalization, MiSight expansion, fertility growth, legal clarity, and buybacks; the main overhangs are MIUDELLA, recall liabilities, FX, and the decision to retain CooperSurgical.